Regulation & law · 28/10/2015
National Institutes of Health to Grant Exclusive Patent License for Obesity and Diabetes Treatments
The National Institutes of Health is considering granting an exclusive patent license to develop therapeutics for obesity, type 2 diabetes, fatty liver disease, and liver fibrosis in humans, as outlined in patent applications related to CB1 receptor mediating compounds.